Tirzepatide (Mounjaro) for Weight Loss in Bangalore

What is Tirzepatide?

Tirzepatide is a first-in-class dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist. Unlike single-mechanism medications that target only one hormone pathway, Tirzepatide simultaneously activates two complementary hormone receptors that regulate appetite, metabolism, and blood sugar. This dual-action mechanism is what gives Tirzepatide its superior efficacy. Compare all GLP-1 medications →

The GIP component is what sets Tirzepatide apart from other GLP-1 medications. GIP is a hormone that enhances insulin secretion, improves fat metabolism, and may have direct effects on the brain's appetite centers. By combining GLP-1 and GIP activation in a single molecule, Tirzepatide produces a synergistic effect that is greater than the sum of its parts. The SURMOUNT-1 clinical trial, published in the New England Journal of Medicine, showed that patients taking Tirzepatide at the highest dose (15 mg weekly) achieved an average weight loss of 22.5% — over 24 kg (53 pounds) — after 72 weeks.

Tirzepatide was originally approved by the FDA for the management of type 2 diabetes under the brand name Mounjaro. Following its remarkable results in weight loss trials, it has become the most sought-after medication for obesity treatment, with demand far exceeding supply in many parts of the world. At EQUA, we help eligible patients access Tirzepatide therapy with proper endocrinologist supervision.

How Tirzepatide Works

Tirzepatide's dual mechanism of action produces weight loss through several coordinated pathways:

• GLP-1 Receptor Activation: Reduces appetite, slows gastric emptying, and increases feelings of fullness, similar to Semaglutide and other GLP-1 medications.
• GIP Receptor Activation: Enhances insulin secretion in response to meals, improves fat metabolism and energy expenditure, and may directly reduce food intake through brain receptor activation. GIP also has direct effects on adipose tissue that promote fat utilization.
• Synergistic Appetite Suppression: The combination of GLP-1 and GIP activation produces stronger and more sustained appetite reduction than either mechanism alone. Patients report significantly reduced food thoughts and cravings.
• Improved Metabolic Rate: Early evidence suggests that GIP activation may help preserve or even increase energy expenditure during weight loss, counteracting the natural metabolic slowdown that typically occurs with caloric restriction.

This comprehensive approach addresses multiple biological drivers of obesity simultaneously, making Tirzepatide the most effective pharmacological option currently available for weight management.

The SURPASS-2 clinical trial directly compared Tirzepatide with Semaglutide in patients with type 2 diabetes. The results demonstrated Tirzepatide's superiority across all measured outcomes. Here is how the two medications compare:

• Weight Loss Efficacy: Tirzepatide produces 15-22% average body weight loss versus 10-15% with Semaglutide. At the highest doses, Tirzepatide patients lose approximately 8-10% more body weight on average.
• Mechanism of Action: Tirzepatide is a dual GLP-1/GIP agonist, while Semaglutide is a single GLP-1 agonist only. The additional GIP activation is believed to account for Tirzepatide's superior results.
• Blood Sugar Control: Tirzepatide demonstrates superior HbA1c reduction compared to Semaglutide, making it particularly advantageous for patients with type 2 diabetes or prediabetes.
• Side Effect Profile: Both medications have similar side effect profiles, with gastrointestinal effects being most common. Tirzepatide may have a slightly higher incidence of nausea at the start of treatment.
• Dosing Frequency: Both are once-weekly injections with similar titration protocols.

Tirzepatide follows a structured dose escalation schedule to ensure tolerability and safety:

• Weeks 1-4: 2.5 mg once weekly (starting dose)
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly
• Week 21 onwards: 15 mg once weekly (maximum dose)

Not all patients need to reach the maximum dose to achieve their weight loss goals. Our endocrinologists determine the optimal dose for each patient based on their response, tolerance, and weight loss targets. Some patients achieve excellent results at intermediate doses like 10 mg or 12.5 mg weekly.

The cost of Tirzepatide (Mounjaro) in Bangalore varies based on the prescribed dose. Estimated monthly costs are:

• Starting doses (2.5-5 mg weekly): Rs. 14,000 - Rs. 18,000 per month
• Intermediate doses (7.5-10 mg weekly): Rs. 18,000 - Rs. 24,000 per month
• Higher doses (12.5-15 mg weekly): Rs. 24,000 - Rs. 28,000 per month

At EQUA, we believe in transparent pricing. Our consultation includes a detailed discussion of medication costs, expected duration of treatment, and any available package options. We help patients navigate the cost of therapy and provide guidance on insurance coverage where applicable.

Tirzepatide has been extensively studied in the SURPASS and SURMOUNT clinical trial programs. Its safety profile is well-established, with the most common side effects being gastrointestinal in nature:

• Nausea: The most frequently reported side effect, occurring in approximately 40% of patients. It is usually mild to moderate and improves with time and gradual dose escalation.
• Diarrhea and Vomiting: Reported by 20-30% of patients, typically during the first few weeks. Staying well-hydrated and eating smaller, frequent meals helps manage these symptoms.
• Constipation and Abdominal Pain: Can occur but are generally manageable with dietary adjustments and over-the-counter remedies as needed.
• Decreased Appetite: While this is a desired effect for weight loss, it can occasionally be excessive. Our endocrinologists ensure patients maintain adequate nutrition during treatment.

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN-2. It carries a boxed warning regarding thyroid C-cell tumors based on animal studies, though the clinical significance in humans remains unclear. A thorough medical evaluation is mandatory before starting therapy.

Am I Eligible for Tirzepatide?

Tirzepatide (Mounjaro) is prescribed for adults who meet these criteria:

• BMI ≥ 30 (obese range), OR
• BMI 27–29.9 (overweight) with at least one weight-related condition: Type 2 Diabetes, PCOS, hypertension, high cholesterol, sleep apnoea, or fatty liver disease
• BMI ≥ 25 for Indian patients — lower thresholds apply due to higher metabolic risk in South Asian populations

Tirzepatide is particularly well-suited for patients with Type 2 Diabetes who also need weight management, due to its superior blood sugar control. Your assessment at EQUA includes body composition analysis, metabolic blood panels, and medical history review.

Not suitable if you have a personal/family history of medullary thyroid carcinoma, MEN-2 syndrome, are pregnant/breastfeeding, or have a history of pancreatitis.

Take our free obesity risk assessment →

Drug Interactions & Precautions

• Insulin & sulfonylureas: Higher hypoglycaemia risk than Semaglutide due to dual receptor action. Dose reduction usually required.
• Oral contraceptives: Delayed stomach emptying may reduce absorption. Consider alternative contraception.
• Warfarin/DOACs: Closer INR monitoring recommended.
• Pregnancy: Discontinue at least 2 months before planned pregnancy. Not recommended during breastfeeding.
• Thyroid monitoring: Due to the boxed warning on thyroid C-cell tumors, our endocrinologists may recommend periodic thyroid monitoring.

How to Inject Tirzepatide

Tirzepatide (Mounjaro) comes as a pre-filled pen. Our nursing team demonstrates the technique:

• Sites: Abdomen (2 inches from navel), thigh, or upper arm. Rotate sites each week.
• Technique: Clean with alcohol swab, pinch skin, insert needle at 90°, press button, hold 10 seconds.
• Timing: Same day each week, with or without food.
• Missed dose: Take within 48 hours. If more than 48 hours, skip and resume schedule. Do not double-dose.
• Storage: Refrigerate unopened pens (2–8°C). Once opened, room temperature (<30°C) for up to 21 days (shorter than Semaglutide — check pen instructions).

What Happens When You Stop Tirzepatide?

Weight regain is common after stopping. Studies show 50–80% of lost weight may return within 1–5 years. Tirzepatide is generally prescribed as a long-term treatment. At EQUA, we combine medication with lifestyle modifications and offer gradual dose reduction protocols when appropriate.

Learn why obesity is a chronic disease →

Tirzepatide FAQs